Alexion Pharmaceuticals, Inc. focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome is the key product of this New Haven, CT-based company. In this scenario, investors focus should remain on Soliris performance.
Under its metabolic franchise, the company markets Strensiq for the treatment of patients with pediatric-onset hypophosphatasia (HPP) and Kanuma for the treatment of patients with lysosomal acid lipase deficiency (LAL-D).
The company’s track record has been impressive. Over the last four quarters, the company has beaten estimates on all four occasions. Overall, Alexion has posted an average positive earnings surprise of 15.31% for the trailing four quarters.
Currently, Alexion has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Alexion surpassed earnings expectations in the second quarter of 2018. Our consensus called for EPS of $1.69, and the company reported EPS of $2.07.
Revenue: Revenues, also, beat expectations. Alexion posted revenues of $1.05 billion, compared to our consensus estimate of $981 million.
Key Stats: Soliris sales increased 10% in the quarter to $898.2 million. During the quarter the company submitted applications in the United States and EU for the approval of ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria (PNH).
The company also completed the Wilson Therapeutics acquisition during the quarter.
2018 Guidance: The company raised its earnings per share and revenue guidance for 2018. It expects earnings per share to be in the range $7.00 to $7.15 up from the previous range of $6.75 to $6.90. It projects revenues to be in the range of $3.98 to $4.01 billion up from its previous expectation of $3.93 to $3.99 billion. The Zacks Consensus Estimate for earnings for 2018 was $7.04 per share while for sales it was $4.01 billion.
Share Price Impact: Share price increased 3.5% in pre-market trading.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>
Image: Bigstock
Alexion (ALXN) Tops Q2 Earnings and Revenues Beat Estimates
Alexion Pharmaceuticals, Inc. focuses on the development and commercialization of life-transforming drugs for treating patients suffering from ultra-rare disorders. Soliris approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome is the key product of this New Haven, CT-based company. In this scenario, investors focus should remain on Soliris performance.
Under its metabolic franchise, the company markets Strensiq for the treatment of patients with pediatric-onset hypophosphatasia (HPP) and Kanuma for the treatment of patients with lysosomal acid lipase deficiency (LAL-D).
The company’s track record has been impressive. Over the last four quarters, the company has beaten estimates on all four occasions. Overall, Alexion has posted an average positive earnings surprise of 15.31% for the trailing four quarters.
Currently, Alexion has a Zacks Rank #2 (Buy), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings: Alexion surpassed earnings expectations in the second quarter of 2018. Our consensus called for EPS of $1.69, and the company reported EPS of $2.07.
Revenue: Revenues, also, beat expectations. Alexion posted revenues of $1.05 billion, compared to our consensus estimate of $981 million.
Key Stats: Soliris sales increased 10% in the quarter to $898.2 million. During the quarter the company submitted applications in the United States and EU for the approval of ALXN1210 in patients with paroxysmal nocturnal hemoglobinuria (PNH).
The company also completed the Wilson Therapeutics acquisition during the quarter.
2018 Guidance: The company raised its earnings per share and revenue guidance for 2018. It expects earnings per share to be in the range $7.00 to $7.15 up from the previous range of $6.75 to $6.90. It projects revenues to be in the range of $3.98 to $4.01 billion up from its previous expectation of $3.93 to $3.99 billion. The Zacks Consensus Estimate for earnings for 2018 was $7.04 per share while for sales it was $4.01 billion.
Share Price Impact: Share price increased 3.5% in pre-market trading.
Alexion Pharmaceuticals, Inc. Price and EPS Surprise
Alexion Pharmaceuticals, Inc. Price and EPS Surprise | Alexion Pharmaceuticals, Inc. Quote
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>